Presenter: Mark Emalfarb, CEO

Market/Indication: Fungal based expression system speeds up the development and production of biologics

Funding Stage: Publicly Listed Ticker: NASDAQ: DYAI

Development Stage: Drug Discovery

Location: United States

Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system – but most importantly to save lives.